[{"arm_notes": "", "treatment_id": null, "treatment_name": "Experimental Group 1: FINLAY-FR-2 25 \u00b5g RBD-TT; Intramuscular (IM); 0.5 mL; 0 \u2013 28 days. Presentation: Vial with single dose. Experimental Group 2: FINLAY-FR-2 25 \u00b5g RBD-TT; IM; 0.5 mL; 0 \u2013 28 days + FINLAY-FR-1A (50 \u00b5g d-RBD+ alumina; IM; 0.5 mL) as booster dose 56 days. Presentation: Vial with single dose. Placebo Group: IM; 0.5 mL; 0 \u2013 28 days. Presentation: Vial with single dose.;Immunogenicity; Vaccine;Immunotherapy; Active;Vaccination;Injections; Intramuscular", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "25 \u00b5g;2;Day0-28;IM", "treatment_id": 515, "treatment_name": "Finlay-fr-2 anti-sars-cov-2 vaccine", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "(25 \u00b5g;2;Day0-28)+booster(50 \u00b5g;1;Day56);IM", "treatment_id": 1519, "treatment_name": "Finlay-fr-1a anti-sars-cov-2 vaccine+finlay-fr-2 anti-sars-cov-2 vaccine", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]

[{"arm_notes": "", "treatment_id": null, "treatment_name": "Experimental Group 1: FINLAY-FR-2 25 ug RBD-TT; Intramuscular (IM); 0.5 mL; 0 - 28 days. Presentation: Vial with single dose. Experimental Group 2: FINLAY-FR-2 25 ug RBD-TT; IM; 0.5 mL; 0 - 28 days + FINLAY-FR-1A (50 ug d-RBD+ alumina; IM; 0.5 mL) as booster dose 56 days. Presentation: Vial with single dose. Placebo Group: IM; 0.5 mL; 0 - 28 days. Presentation: Vial with single dose.;Immunogenicity; Vaccine", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]